Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Lite Strategy Inc

LITS ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Financials · Investment Management & Fund Operators ·

USA Micro Cap Analyst: N/A

Last Close

$0.89

▼ -1.01%

Market Cap $30.16M · Vol 23.09K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$30.16M

Micro Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

N/A

YoY

RSI (14)

36.03

Momentum

Beta

0.18

vs Market

52W High

$5.50

83.88% below

52W Low

$0.69

28.11% above

Volume

23.09K

Avg 33.49K

P/B

0.97

Price-to-book

ROE

N/A

Return on equity

Free Float

98.76%

Public shares

Shariah Compliance8 STANDARDS

✗ Lite Strategy Inc (LITS) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does LITS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.31%

-11.07%

-27.34%

-20.85%

YTD

-32.84%

-81.91%

-83.70%

-97.93%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-15,945,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-53.45% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.97
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	34.03M

Technical Indicators

50-Day SMA	$0.92
200-Day SMA	$1.24
RSI (14)	36.03
Beta	0.18
52-Week High	$5.50
52-Week Low	$0.69

Volume Today	23.09K
Avg Daily Volume (30D)	33.49K
Relative Volume	0.69x
Volatility (10D)	42.84
Volatility (30D)	45.23
Free Float	98.76%

Analyst Consensus

N/A

Current Price $0.89

Mean Target N/A

52W Low$0.69 52W High$5.50

Current

Target

$0.69 $5.50

Current Analyst target

· 0 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SBWG10

ISINUS55279B3015

CountryUnited States of America

Sub-IndustryInvestment Management & Fund Operators (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

DRR.AX Deterra Royalties Ltd -2.31% 4084.SE Derayah Financial Company SJSC +0.05% DBIH.OM Al Batinah Development and Investment Holding Co SAOG +0.00% ROKO B.ST Roko AB (publ) +1.67% ALSAFAT.KW Al Safat Investment Company KSCP -1.54%

Company Profile

Lite Strategy, Inc., formerly MEI Pharma, Inc., is a Litecoin treasury company. The Company accumulates pure LTC through active treasury management and concentrates holdings per share as the ultimate metric of shareholder value. It is a clinical-stage pharmaceutical company focused on the development of differentiated cancer therapies intended to improve outcomes for patients. Its approach to oncology drug development is to evaluate its drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs. The portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3Kd inhibitor. Voruciclib is a selective orally administered CDK9 inhibitor with potential to treat both hematological malignancies and solid tumors. Voruciclib, a selective orally administered inhibitor of CDK9, is in clinical development for acute myeloid leukemia.